Trial Profile
A 24 Week Randomized, Double-blind, Placebo-controlled Withdrawal Trial With a 16 Week Open-label lead-in Phase, and 64 Week Open-label Follow-up, to Evaluate the Effect on Clinical Response and the Safety of Tocilizumab in Patients With Active Polyarticular-course Juvenile Idiopathic Arthritis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Dec 2021
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms CHERISH
- Sponsors Roche
- 01 Mar 2019 Results of pooled analysis from NCT00642460 and NCT0098822 determining whether neutropenia is associated with increased risk for infection, published in The Journal of Rheumatology
- 01 Jul 2018 Results (n=187) of post-hoc analysis assessing growth rates in patients with polyarticular-course juvenile idiopathic arthritis (pcJIA) treated with Tocilizumab in this 2-year CHERISH trial, published in The Journal of Rheumatology.
- 16 May 2014 Results published in the Annals of the Rheumatic Diseases.